How do I interpret a triglycerides trend across three draws?

I have the full paper rather than the abstract, and the supplementary appendix.

I have the document in front of me and I can read the numbers. What I cannot do is interpret them.

I am reasonably comfortable with statistics and completely uncomfortable with chromatography, or vice versa.

Which parts of this are informative and which are decoration?

Answer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.

A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.

Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.

Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.

The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.

Keep the full report, not the number. You will need the units and the interval later.

The short version: a small, well-chosen panel with a baseline beats a large one without.

A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.

Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.

Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.

Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.

One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.

Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.

Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.

Baseline first, then a repeat under identical conditions. Everything else is secondary.

Before reacting to any single value, check whether it is outside the interval by an amount larger than the assay's own variation.

Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.

External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.

Decide the action for each result before you order the test.

This is answerable, and the answer is mostly about which tests rather than how many.

Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.

Research-use compounds are not approved for human use, and no panel makes that safer.

Same laboratory, same time, same fasting state, or the comparison is not a comparison.

edited 4 Jul 2025 by fresh_bac — updated for the 2026 guidance change